Incyte (INCY) financials
Incyte revenue and earnings by year
Incyte's revenue was $5.14 billion in the fiscal year to December 31, 2025, up 21.2% from the year before. Net income was $1.29 billion, 25.0% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 18.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.14 | 4.24 | 3.70 | 3.39 | 2.99 | 2.67 | 2.16 | 1.88 | 1.54 | 1.11 |
| Revenue growth | 21.2% | 14.8% | 8.9% | 13.7% | 12.0% | 23.5% | 14.7% | 22.5% | 38.9% | — |
| Gross profit | 4.77 | 3.93 | 3.44 | 3.19 | 2.84 | 2.54 | 2.04 | 1.79 | 1.46 | 1.05 |
| Gross margin | 92.8% | 92.6% | 93.1% | 93.9% | 94.9% | 95.1% | 94.7% | 95.0% | 94.8% | 94.7% |
| Operating income | 1.51 | 0.06 | 0.62 | 0.58 | 0.59 | -0.26 | 0.42 | 0.16 | -0.24 | 0.16 |
| Operating margin | 29.5% | 1.4% | 16.8% | 17.1% | 19.6% | -9.9% | 19.5% | 8.3% | -15.3% | 14.7% |
| Net income | 1.29 | 0.03 | 0.60 | 0.34 | 0.95 | -0.30 | 0.45 | 0.11 | -0.31 | 0.10 |
| Net margin | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% | -11.1% | 20.7% | 5.8% | -20.4% | 9.4% |
| Diluted EPS | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | -$1.40 | $2.05 | $0.51 | -$1.56 | $0.54 |
| Free cash flow | 1.35 | 0.25 | 0.46 | 0.89 | 0.57 | -0.31 | 0.63 | 0.26 | -0.20 | 0.18 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open INCY in Markets.
How Incyte makes money
Revenue by segment in the quarter to September 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $1.32B | 84.5% |
| JAKAVI Royalty Revenues | $132M | 8.5% |
| Milestone & Contract Revenues | $49.8M | 3.2% |
| OLUMIANT Royalty Revenues | $39.1M | 2.5% |
| Other Product Royalty Revenues | $12.6M | 0.8% |
| TABRECTA Royalty Revenues | $6.83M | 0.4% |
See also: INCY valuation and P/E history · INCY returns
No forecast, no recommendation. This page describes Incyte from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.